Pj Pharma

What Pj Pharma does

PJ Pharma is the B2B, ready-to-market distribution division of Italian pharmaceutical group Gruppo FarmaImpresa, operating from Teverola (Caserta), Italy, and standing up as a standalone entity in 2025. It commercialises a catalog of 200+ CE-marked medical devices, food supplements, and dermocosmetics across 12 therapeutic areas (including gynaecology, paediatrics, gastroenterology, osteoarticular, ENT/respiratory, dermatology, and others), distributing the portfolio through pharmaceutical distributors and private-label partners in more than 50 countries. Revenue is generated from one-time sales of pre-formulated, ready-to-commercialise products and from private-label/OEM licensing arrangements in which PJ Pharma supplies formulations plus regulatory, research, and marketing services to distributors that rebrand them for their own markets.

The technical foundation is supplied by parent Gruppo FarmaImpresa's proprietary formulation technologies in bioavailability enhancement, ingredient stability, and controlled release of actives — capabilities the company applies to medical devices, supplements, and dermocosmetics rather than to software or AI. Differentiation rests on regulatory readiness (CE-marked SKUs that bypass long internal development cycles for buyers), a clinical evidence base (e.g., published GERD outcomes on the Reflusod device showing a 71% reduction in GERD-HRQL), portfolio breadth, and an event-led B2B go-to-market built around major industry trade shows such as CPHI Milano 2026.

The company is privately held within Gruppo FarmaImpresa with no external disclosed funding, no public revenue figures, and a disclosed headcount of roughly 7 employees — consistent with a focused commercial/distribution brand operating on top of an established manufacturing parent. Pricing is not publicly disclosed and is built around B2B quotes and volume-based custom pricing per market.

Name

Pj Pharma

Legal name

PJ Pharma

Website

https://pjpharma.it

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

PJ Pharma is the ready-to-market B2B division of Italian pharma group Gruppo FarmaImpresa, distributing 200+ CE-marked medical devices, food supplements, and dermocosmetics to pharmaceutical distributors and private-label partners across 50+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Food Manufacturing (311), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Food And Kindred Products (2000), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Full-Line Pharmaceutical Wholesalers (HLAIAJAA), Pharmacy Supply Chain & Secondary Distribution (Repackagers/Redistributors) (CRAOAHAC)

Keywords

• Pharmaceutical contract manufacturing
• Private label supplements
• Medical device distribution
• Food supplement manufacturing
• Dermocosmetic private label

Headquarters

HQ city

Teverola

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Ready-to-Market Product Sales: Sale of pre-formulated and validated medical devices, food supplements, and dermocosmetics to B2B customers including distributors and pharmaceutical companies. Products are already compliant and ready for commercialization.
2. Private Label Solutions: Customization and branding of existing formulations for individual distributors or target markets. Includes full support for regulatory, research, and marketing aspects.
3. Regulatory and Research Services: Support services including regulatory affairs, clinical research, and marketing support for product commercialization in different markets.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Pj Pharma is the ready-to-market commercial division of Gruppo FarmaImpresa, selling pre-formulated, CE-marked medical devices, food supplements, and dermocosmetics to B2B distributors and pharmaceutical companies. The portfolio of more than 200 products spans 12 therapeutic areas and is available under the company's own brand or in private label configurations, with full regulatory, research, and marketing support included.

Product overview

PJ Pharma is the ready-to-market line of Gruppo FarmaImpresa, offering a portfolio of over 200 CE-marked medical devices, food supplements, and dermocosmetics distributed across more than 50 countries. The product portfolio covers 12 therapeutic areas: Gynecology (34 products), Pediatrics (37 products), ENT/Respiratory/Immunology (20 products), Gastroenterology (22 products), Nervous System (10 products), Osteoarticular (13 products), Cardiovascular (4 products), Endocrinology & Metabolism (4 products), Dermatology & Trichology (7 products), Urology (8 products), Hepatology (2 products), and Ophthalmology (2 products). Products are available in multiple pharmaceutical forms including stick-packs, ovules, vaginal gels, syringes, oral drops, tablets, vials, nasal sprays, soft capsules, capsules, sachets, vaginal douches, oral sprays, syrups, and emulsions. The portfolio includes standalone products like Oralia (oral spray), Flogorex Compresse (anti-inflammatory supplement), Rilefast Mag and Reflucalm Plus (GERD devices), Revaginal Lavanda (vaginal irrigation), and Marisleep (pediatric sleep supplement), alongside private label customization options.

Differentiator

Problem solved

Functional benefit

Brands

• Armonita: Related brand website under Gruppo FarmaImpresa network
• Revaginal
• Comil
• Oralia
• Flogorex
• Rilefast Mag
• Reflucalm Plus
• Rilefast CE Spray
• Revaginal Lavanda
• Marisleep

Products and services

• Oralia Medical device in oral spray format containing chlorhexidine, hyaluronic acid, aloe vera, tea tree oil, and bisabolol. Indicated for throat irritation, mouth ulcers, gingival inflammation, and oral mucosal discomfort. Sold via B2B distribution channels to pharmaceutical distributors and healthcare companies.
• Flogorex Compresse Food supplement in tablet form containing bromelain (2500 GDU) and Boswellia serrata (65% boswellic acids) for support of osteo-articular inflammation, muscle pain, and localized inflammatory states. Sold to B2B distributors and pharmaceutical companies for resale under own brand or private label.
• Rilefast Mag Medical device in stickpack (emulsion) format containing Magnesium Alginate and low molecular weight Hyaluronic Acid. Indicated for treatment of moderate-severe Gastroesophageal Reflux Disease (GERD) symptoms. Distributed to B2B partners.
• Reflucalm Plus Multi-action oral gel medical device containing double Alginate (Magnesium and Sodium), Sodium Hyaluronate, Myrrh extract, Simeticone, and Guar seed flour. Indicated for moderate-severe GERD symptoms and reflux gas. Distributed to B2B partners.
• Rilefast CE Spray Medical device spray (MDR) containing Simeticone in olive oil suspension with Vitamin E and CoQ10 as antioxidants. Indicated for relief of gastrointestinal gas-related disorders including infant colic, meteorism, and gas-related pain in neonates, children, and adults. Distributed to B2B partners.
• Revaginal Lavanda Vaginal irrigation medical device containing low molecular weight Hyaluronic Acid, Lactic Acid, PVP, Disodium EDTA, Potassium Sorbate, and Sodium Benzoate. Indicated for protection and regeneration of vaginal and vulvar mucosa and treatment of vulvovaginitis symptoms. Distributed to B2B partners.
• Marisleep Food supplement in oral drops format containing Melatonin, B Vitamins (B1, B2, B6), and Folic Acid. Specifically formulated for neonates and children to promote relaxation, improve sleep quality, and support regulation of sleep-wake cycles. Distributed to B2B partners.
• Reflusod Oral CE-marked medical device containing Hyaluronic Acid and Alginate for treatment of moderate-severe GERD. Creates a mechanical protective barrier on the gastroesophageal mucosa, limiting acid contact and reducing esophageal irritation. Distributed to B2B partners.
• Depalife Emulsion-based food supplement containing Omega 3 (EPA, DHA) and Vitamins that supports brain development, growth, and combats fatigue. Distributed to B2B partners.
• Omegarex Food supplement for children containing EPA, DHA, Zinc, and Magnesium that combats fatigue, mental stress, and improves concentration. Distributed to B2B partners.
• Balatus Complete oral solution for dry cough, productive cough, and sore throat that protects mucosa and provides hydration. Distributed to B2B partners.
• Broncolisin Syrup for dry and productive cough containing Honey, Propolis, Marshmallow, Sundew, and Grindelia that promotes respiratory tract well-being. Distributed to B2B partners.
• Idanil Solution Medical device with Hyaluronic Acid, Chlorhexidine, and Aloe Vera indicated for hemorrhoids, anal fissures, and erythema. Soothes and repairs mucosa. Distributed to B2B partners.
• Propelin Oral Gel Cosmetic product for mouth ulcers and oral pain containing Propolis and Hyaluronic Acid. Creates a protective barrier and rapidly soothes oral lesions. Distributed to B2B partners.
• Propelin OS Oral spray treatment for throat containing Propolis, Echinacea, and Peppermint that calms pain, inflammation, and mouth dryness. Distributed to B2B partners.
• Private Label Solutions B2B service for pharmaceutical distributors and healthcare companies providing customization and branding of Pj Pharma's existing medical device, food supplement, and dermocosmetic formulations under partner brands. Includes regulatory affairs, research, and marketing support for commercialization in different markets.

Quantifiable outcome

• 71% reduction in GERD-HRQL score in clinical study on Reflusod product
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Gruppo FarmaImpresacoreStrategic or Co-development PartnerPJ Pharma is the ready-to-market division of Gruppo FarmaImpresa, leveraging the parent company's expertise in developing innovative technologies for bioavailability, stability, and active ingredient release. Gruppo FarmaImpresa provides the technological foundation and manufacturing capabilities that underpin PJ Pharma's product portfolio.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Menarini Group: Large Italian pharmaceutical group with extensive international distribution across primary care and specialty therapeutics. Comparable as a broad incumbent peer in the Italian pharma distribution and manufacturing space.
• Dompé: Italian biopharmaceutical company with diverse primary care and specialty products. Comparable as a larger Italian pharma peer with international distribution and a broad therapeutic-area portfolio across both pharmaceuticals and medical devices.
• Catalent: Global CDMO providing contract development, manufacturing, and packaging for pharmaceuticals and consumer health products. Comparable as a broad contract manufacturing peer in the B2B pharmaceutical/supplement production space.
• Chiesi Farmaceutici: Established Italian pharmaceutical group with global distribution across multiple therapeutic areas. Comparable as a broad incumbent in the Italian pharma space with international commercial reach exceeding PJ Pharma's footprint.
• Recordati: Major Italian pharmaceutical group with diversified specialty and primary care products sold internationally. Comparable as an Italian pharma incumbent operating across multiple therapeutic categories with established B2B and B2C channels.

Direct peers

• Recipharm: European CDMO offering contract development and manufacturing for pharmaceutical and medical device companies with private label capabilities. Comparable to PJ Pharma's B2B manufacturing and white-label service model across multiple dosage forms.
• Aenova: European CDMO specializing in solid, semi-solid, and liquid dosage forms for pharmaceuticals and supplements with private label services. Comparable to PJ Pharma's contract manufacturing model across multiple therapeutic areas and dosage formats.
• Italfarmaco: Italian pharmaceutical group with a diversified portfolio across multiple therapeutic areas and B2B/private label offerings. Comparable to PJ Pharma as a domestic Italian pharma manufacturer-distributor with broad therapeutic coverage and international presence.
• Biofarma Group: Italian CDMO specializing in food supplements, medical devices, and cosmetic contract manufacturing with private label services. Highly comparable to PJ Pharma as a domestic Italian contract manufacturer offering ready-to-market products across multiple therapeutic areas.

Regional players

• Polpharma Group: Central European pharmaceutical manufacturer with broad portfolio across multiple therapeutic areas and international B2B distribution. Comparable as a regional pharma manufacturer with private label and licensing arrangements similar to PJ Pharma's model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pj-pharma

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pj Pharma